News

Article

Jyoti D. Patel on the Progress of Immunotherapy in NSCLC

Author(s):

Jyoti D. Patel

Key Takeaways

  • Immunotherapy is showing promise as a treatment for non-small cell lung cancer (NSCLC), with significant advancements reported at the 2015 ASCO meeting.
  • Jyoti D. Patel highlighted the progress in immunotherapy for NSCLC, emphasizing its potential to improve patient outcomes.
SHOW MORE

Jyoti D. Patel, ASCO expert, associate professor, Northwestern University Feinberg School of Medicine, discusses the progress of immunotherapy as treatment for patients with non-small cell lung cancer.

Jyoti D. Patel, ASCO expert, associate professor, Northwestern University Feinberg School of Medicine, discusses the progress of immunotherapy as treatment for patients with non-small cell lung cancer (NSCLC). Patel is reporting on data presented at the 2015 annual meeting of the American Society of Clinical Oncology, a gathering of nearly 30,000 oncology professionals in Chicago.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Waldenstrom macroglobulinemia is often slow growing, with high survival but lower quality of life over time, explained researcher Alisha Kimble.
Image of woman.
Image of two doctors and text.
Combining JNJ-1900 with Keytruda may improve distant control of lung cancer, explained by Dr. Jared Weiss.
image of serzan.
Dr. Breelyn Wilky explains that personalized treatments are helping improve outcomes for patients with gastrointestinal stromal tumors.
Image of two doctors with text.
Image of doctors with text.
Treatment with zanzalintinib plus Opdivo and Opdualag is an option worth exploring in patients with previously untreated clear cell renal cell carcinoma
Image of two doctors and text.
Related Content
Datroway received accelerated FDA approval for adults with EGFR+ advanced NSCLC: © stock.adobe.com.
June 23rd 2025

FDA Approves Datroway for EGFR-Mutated Advanced Lung Cancer

Spencer Feldman
Datroway received accelerated FDA approval for adults with EGFR+ advanced non-small cell lung cancer after EGFR-targeted and platinum chemotherapy.
CURE Cancer Horizons logo
February 26th 2024

FDA Approvals from February 2024

Alex Biese Brielle Benyon
February brought in multiple FDA approvals in the oncology space. Here’s an overview of some of the most recent ones.
Dr. Jared Weiss explained that radiation for lung cancer may ease symptoms or aim to cure, with newer targeted forms potentially boosting immune responses.
June 19th 2025

Exploring Palliative and Curative Radiation for Lung Cancer

Dr. Jared Weiss
Dr. Jared Weiss explained that radiation for lung cancer may ease symptoms or aim to cure, with newer targeted forms potentially boosting immune responses.
Guidelines for Childhood Neuroblastoma, FDA Decisions and More
February 12th 2024

Guidelines for Childhood Neuroblastoma, FDA Decisions and More

Alex Biese Brielle Benyon
Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews
Image of lung.
June 18th 2025

Recent SCLC Data May Impact How Patients Are Treated Day-to-Day

Ryan Scott
Various trials within the small cell lung cancer space were brought to light following recent data, impacting how patients will be treated in the future.
Image of hands.
June 18th 2025

The Person Behind Their Diagnosis: Understanding the Patient

Ryan Scott
Dr. Joshua Sabari and Jackie Herigodt discuss the Imerman Angels organization and the importance of recognizing the person behind their cancer diagnosis.